Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Jeffrey Cohen(Cleveland Clinic), Alasdair Coles(University of Cambridge), Douglas L. Arnold(McGill University), Christian Confavreux(Hospices Civils de Lyon), Edward Fox(Central Texas Neurology Consultants), Hans-Peter Hartung(Heinrich Heine University Düsseldorf), Eva Havrdová(Charles University), Krzysztof Selmaj(Medical University of Lodz), Howard L. Weiner(Brigham and Women's Hospital), Elizabeth Fisher(Cleveland Clinic), Vesna Brinar(University Hospital Centre Zagreb), Gavin Giovannoni(Queen Mary University of London), M. Stojanovic(Clinical Centre of Kragujevac), Bella Ertik, Stephen Lake, David Margolin, Michael Panzara, D. A. S. Compston(University of Cambridge)
The Lancet
November 1, 2012
Cited by 1,196

Abstract


Related Papers

No related papers found

Powered by citation graph analysis